Of the included studies, five were RCTs [20,21,22,23,24] and five were cohort studies [25,26,27,28,29]
Research published in cardiovascular journals indicates these effects persist across different patient populations, including those with prediabetes, type 2 diabetes, and obesity without diabetes
This finding identifies ferroptosis as an important contributor to MS pathology and demonstrates that ferroptosis targeting might be a promising novel future treatment for MS patients, eventually supplementing current immunosuppressive disease-modifying therapies
However, regulatory non-compliance is a concern, resulting in inadequate legal controls and inconsistencies in product standardization